SCHEMBL4766518

SCHEMBL4766518

CCCC[Sn](CCCC)(CCCC)c1ccc(O[C@@H](C)COC(C)=O)cc1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
MTNR1A P48039 2/20 0.36
MTNR1B P49286 2/20 0.36
GPR88 Q9GZN0 1/20 0.34
MAPT P10636 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
LMNA P02545 1/20 0.33
ACACB O00763 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766519 1.00 ALDH1A1 (0.37) ALDH1A1MTNR1AMTNR1BGPR88MAPT
SCHEMBL4769212 1.00 ALDH1A1 (0.37) ALDH1A1MTNR1AMTNR1BGPR88MAPT
SCHEMBL4772400 0.81 POLB (0.35) ALDH1A1MTNR1AMTNR1BMAPTPOLB
SCHEMBL4773424 0.79 TSHR (0.39) MAPTPOLBLMNAACACBTSHR
SCHEMBL4771899 0.79 TSHR (0.39) MAPTPOLBLMNAACACBTSHR
SCHEMBL4771904 0.79 TSHR (0.39) MAPTPOLBLMNAACACBTSHR
SCHEMBL4772112 0.77 LMNA (0.47) ALDH1A1MAPTPOLBL3MBTL1LMNA
SCHEMBL4772404 0.77 ALDH1A1 (0.47) ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL4772108 0.75 ALDH1A1 (0.35) ALDH1A1L3MBTL1TSHR
SCHEMBL1919531 0.74 AHR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885MTNR1A 126/4885MTNR1B 154/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885MTNR1A 103/4885MTNR1B 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.